This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2016;57(3):728-30.

doi: 10.3109/10428194.2015.1076930. Epub 2015 Oct 5.

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Affiliations

PMID: 26674111
PMCID: PMC4888765
DOI: 10.3109/10428194.2015.1076930

Clinical Trial

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Lukas D Wartman et al. Leuk Lymphoma. 2016.

. 2016;57(3):728-30.

doi: 10.3109/10428194.2015.1076930. Epub 2015 Oct 5.

Affiliation

¹ a Division of Oncology, Department of Medicine , Washington University School of Medicine , St. Louis , MO , USA.

PMID: 26674111
PMCID: PMC4888765
DOI: 10.3109/10428194.2015.1076930

No abstract available

PubMed Disclaimer

Similar articles

A practical review on carfilzomib in multiple myeloma.
Muchtar E, Gertz MA, Magen H. Muchtar E, et al. Eur J Haematol. 2016 Jun;96(6):564-77. doi: 10.1111/ejh.12749. Epub 2016 Mar 9. Eur J Haematol. 2016. PMID: 26893241 Review.
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H. Muchtar E, et al. Br J Haematol. 2016 Jan;172(1):89-96. doi: 10.1111/bjh.13799. Epub 2015 Nov 16. Br J Haematol. 2016. PMID: 26567759
Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael J. Mikhael J. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):241-5. doi: 10.1016/j.clml.2016.01.008. Epub 2016 Feb 4. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26907720 Review.
Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia.
Srour SA, Borders EB, Cherry MA, Holter J, Herman T, Selby GB. Srour SA, et al. Leuk Lymphoma. 2015;56(10):2962-4. doi: 10.3109/10428194.2015.1018250. Epub 2015 Mar 31. Leuk Lymphoma. 2015. PMID: 25721752 No abstract available.
Carfilzomib: a novel agent for multiple myeloma.
Redic K. Redic K. J Pharm Pharmacol. 2013 Aug;65(8):1095-106. doi: 10.1111/jphp.12072. Epub 2013 Apr 24. J Pharm Pharmacol. 2013. PMID: 23837578 Review.

See all similar articles

Cited by

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S, Zhao Y, Lu J, Yu Y, Sun W, Mao X, Chen Z, Xu X, Pan J, Sun S, Yang J. Guan S, et al. Oncotarget. 2016 Nov 15;7(46):75914-75925. doi: 10.18632/oncotarget.12427. Oncotarget. 2016. PMID: 27713150 Free PMC article.
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Besse A, Kraus M, Mendez-Lopez M, Maurits E, Overkleeft HS, Driessen C, Besse L. Besse A, et al. Cells. 2022 Mar 1;11(5):838. doi: 10.3390/cells11050838. Cells. 2022. PMID: 35269460 Free PMC article.
Therapeutic Targeting of the Leukaemia Microenvironment.
Kuek V, Hughes AM, Kotecha RS, Cheung LC. Kuek V, et al. Int J Mol Sci. 2021 Jun 26;22(13):6888. doi: 10.3390/ijms22136888. Int J Mol Sci. 2021. PMID: 34206957 Free PMC article. Review.
The Ubiquitin-Proteasome System in Immune Cells.
Çetin G, Klafack S, Studencka-Turski M, Krüger E, Ebstein F. Çetin G, et al. Biomolecules. 2021 Jan 5;11(1):60. doi: 10.3390/biom11010060. Biomolecules. 2021. PMID: 33466553 Free PMC article. Review.
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.
Zhang L, Niu X, Bi Y, Cui H, Li H, Cheng X. Zhang L, et al. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820948060. doi: 10.1177/1533033820948060. Technol Cancer Res Treat. 2020. PMID: 32924793 Free PMC article.

See all "Cited by" articles

References

1. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013;13(3):339–358. - PubMed
1. Niewerth D, Dingjan I, Cloos J, Jansen G, Kaspers G. Proteasome inhibitors in acute leukemia. Expert Rev Anticancer Ther. 2013;13(3):327–337. - PubMed
1. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007;13(5):1516–1522. - PubMed
1. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446–1454. - PubMed
1. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254–259. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

K08 CA166229/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information